The serum and urine levels qf lidocaine and two active dealkyluted metabolites, monoethylglycinexylidide (MEGX) 
is about half as potent in vivo in dogs. 22 MEGX also has local anesthetic activity6 and convulsant activity in animals.', In fact, the convulsant activity of lidocaine and MEGX seem add i t i~e .~ Although the pharmacologic activity of MEGX in man has not been confirmed, the paresthesia and confusion in a patient of Halkin et al.'%n lidocaine were most likely due to MEGX, since the patient's lidoraine level of 3.5 pglml was within the accepted therapeutic range but the metabolite level of 4.2 pglml was higher than that of the parent drug.
In contrast, the antiarrhythrnic activity of GX in mice was much less than that of l i d o~a i n e ,~~ and this was also seen in vitro in a guinea pig atrium model.4 GX also seemed to potentiate the convulsant activity of MEGX and lidocaine in rats2 and itself had CNS depressant activity in these animals. When GX was infused into two normal subjects to achieve levels as high as, or higher than, those seen clinically after lidocaine, none of the major toxic effects associated with lidocaine therapy were ~bserved.'~ GX, however, did induce headache and adversely affected mental performance in these subjects. GX and MEGX also have the ability to constrict vascular smooth muscle . I 0
Our purpose is to provide serum level and elimination data for lidocaine, MEGX, and GX in cardiac patients of various ages. We also interpret the contribution of MEGX and GX to the pharmacologic activity of lidocaine after serum protein binding is taken into account.
Materials and methods
Our subjects were 33 patients in The New York Hospital Coronary Care Unit who were receiving lidocaine infusions at rates prescribed by their physicians for treatment of arrhythmias. For inclusion in the study, patients must have been receiving lidocaine for more than 24 hr. Patients were assessed for manifestations of lidocaine toxicity, including muscle twitching, paresthesias, dysarthria, drowsiness, disorientation, and seizures at the time blood was drawn for assays. Blood was collected in a syringe and allowed to clot in a glass test tube. Contact with stoppers was avoided. The patients' charts were subsequently reviewed for diagnosis, concurrent drug therapy, clinical laboratory values, and clinical course. In each patient with manifestations of lidocaine toxicity the manifestations subsided after dosage reduction or withdrawal of lidocaine.
Six patients were considered to have lidocaine toxicity, and these were compared to the 27 who did not have toxicity. The following variables were considered: age; creatinine clear- ance; serum bilirubin; SGOT; and serum lidocaine, MEGX, and GX levels. Of the 33 patients, 21 were presumed to be at steady state for lidocaine (infusion rate constant for the 12 hr before evaluation). Serum samples from these subjects were used for the kinetic studies (Table I) . Most of these patients were also receiving propranolol or other P-adrenergicblocking drugs. Propranolol, and probably other P-adrenergic-blocking drugs as well, reduces lidocaine clearance. l8 Most patients had a recent myocardial infarction. The results from three Creatinine clearance (rnllmin) Sex subjects with congestive heart failure are also presented in Table I , but they were not included in the analysis of the data because this disorder is known to decrease the clearance of l i d o~a i n e .~~ Lidocaine, MEGX, and GX (supplied by Astra) were measured in serum or urine as follows: To a 16 x 25 mm Teflon-capped glass extraction tube, add 1 ml of serum or diluted urine, 100 p1 of a 20-pglml aqueous solution of the internal standard (the primary amine of etidocaine [also supplied by Astra]), 200 p1 of 5N NaOH, and 200 p1 of a saturated NaCl so- We used a Waters HPLC equipped with a Model M6000A solvent delivery system, a U-6K injector, a reverse-phase column (micro-BondapakIPhenyl, Waters), a Model 450 variable-wavelength UV detector (Waters) set at 200 nm, and a Varian A25 chart recorder. The mobile phase was Burdick and Jackson acetonitrile in phosphoric acid (0.5 ml in 1 1 water, which is then adjusted to pH 2.8 with 50%
[wlw] NaOH) as a 10: 90 mixture by volume. At the end of each workday, the system is flushed by pumping 20% acetonitrile in water at a flow rate of 2 mllmin for 20 min. We have used this system for 6 mo with no problems. At a flow rate of 2 mllmin, the retention times for GX, MEGX, the internal standard, and lidocaine are 5.8, 7.8, 9.5, and 11.5 min, respectively. A linear relationship between peak height ratios (peak height of compound to peak of the internal standard) and concentration was as follows: 0.1 to at least 4 pglml for GX, 0.25 to at least 8 pglml for MEGX, and 0.5 pglml to at least 16 pglml for lidocaine. A standard curve for GX, MEGX, and lidocaine from either serum or water was always determined concurrently with patient samples.
The coefficient of variation (CV) of the assay for GX, MEGX, and lidocaine, obtained from analysis of six replicate samples from a serum pool containinq 0.5 pglml GX, 1 pglml MEGX, and 2.0 pglml lidocaine, was 4%, 2%, and 2%. The CV of this method, obtained from daily analysis (N = 8) over 4 mo, was 7% for GX, 7% for MEGX, and 7% for lidocaine for our low standard containing 0.25 pglml GX, 0.5 pglml MEGX, and 1 pglml lidocaine. The ratio of GX, MEGX, and lidocaine clearance to endogenous creatinine clearance was calculated from a single voided urine specimen and a simultaneously drawn blood sample. The ratio equals drug concentration in urine times serum creatinine concentration divided by the product of urine creatinine concentration and drug concentration in serum. Serum creatinine was measured by Auto-Analyzer and urine creatinine by the traditional alkaline picrate method with spectrophotometry. Lidocaine clearance (ml/min/kg) was calculated for each patient as follows: Lidocaine clearance = Lidocaine infusion ratellidocaine serum level at presumed steady state. Creatinine clearance for each male subject was calculated from the following equation":
Age fyr) Type
Concentration (pglrnl) For women, this ratio is multiplied by 0.85.
The binding of lidocaine, MEGX, and GX was determined in serum drawn from five normal subjects and from seven patients 2 days after myocardial infarction. The blood was drawn into glass syringes and allowed to clot in 15-ml glass test tubes. Serum from the normal No. of putienrs Lirlocaine subjects was used immediately, whereas that from most of the patients was stored in a frozen state before being used. Aliquots of serum were placed in dialysis tubing (Fisher Scientific). The dialysis tubing was then placed for 24 hr in pH 7.4 phosphate buffer (0.05M) at room temperature containing either 0.5 pglml GX, 2 pglml MEGX, or 2 pglml lidocaine. The samples were then analyzed by HPLC, and the ratio of the drug concentration in buffer to the concentration in dialyzed serum was considered the unbound fraction. GX, MEGX, and lidocaine were added to heparinized whole blood from three subjects to give concentrations of 0.5, 1, and 2 pglml. Half of each subject's blood was added to redstoppered Vacutainers (Becton, Dickenson). These tubes were inverted 10 times, left on their side at room temperature for 30 min, and stored on their side in the refrigerator overnight. The other half of each subject's blood was placed in glass tubes and immediately stored upright in the refrigerator. The samples were then analyzed and compared.
Aliquots of standards containing 20 pglml GX, 20 pglml MEGX, and 20 pglml lidocaine in pH 7.4 phosphate buffer (0.05M) were vortexed with equal volumes of 1-octanol. An aliquot of the original aqueous solution and an aliquot of the buffer after the octanol mixing were then analyzed by HPLC. The partition coefficient equals the concentration in 1-octanol divided by the concentration in buffer. The concentration of the compound in the organic phase is equal to the difference in concentration of the 
Results
The serum level data for lidocaine, MEGX, and GX in 27 nontoxic patients and six toxic patients are listed in Table 11 . The serum MEGXIlidocaine and GXIlidocaine ratios averaged 0.36 + 0.26 and 0.11 + 0.11. Twentyfour of these patients were presumed to be at steady state for lidocaine levels. Patient information, steady-state levels of lidocaine, MEGX, and GX, and lidocaine clearance values in these patients are presented in Table I . The ages of the patients averaged 67 + 10 yr (range, 49 to 86). In these patients at presumed steady state, MEGX serum levels averaged 31% that of lidocaine, whereas GX levels were much lower, averaging only 7.5% that of the parent drug.
Age had no effect on the presumed steadystate serum MEGX levels normalized for lidocaine infusion rate (Fig. 2) lidocaine infusion rate (mglkglmin) = 65.4 -0.17peryearofage(r = -0.05,N = 21). The steady-state serum GX concentration normalized for lidocaine infusion rate declined with age (Fig. 3) . Serum GX (pg/ml)/lidocaine infusion rate (mglkgl min) = 48.13 -0.49 per year of age, but this correlation is not strong (r = -0.39, P 0.1, N = 19). The correlation with age is even weaker when serum GX levels are normalized for lidocaine serum levels (r = -0.17).
We have observed that in 6 of 27 subjects without toxicity, lidocaine levels were above 8 pglml. In one of these patients the lidocaine level was 16.5 pglml (MEGX, 0.77 pglml, and GX, less than 0.1 pglrnl) in serum from blood drawn 0.5 hr after the end of a 34-hr lidocaine infusion. In five of the six subjects with toxicity, lidocaine levels were below 8 pglml. In fact, the only difference between the toxic and the nontoxic patients in this study (Table 11) was that on the average the toxic patients had higher MEGX levels. In the two groups, age, renal function (as determined by creatinine clearances), and liver function (as determined by serum bilirubin and SGOT) did not differ substantially.
The effect of age on lidocaine clearance is presented in Fig. 4 The protein binding of lidocaine, MEGX, and GX in serum (at room temperature) from five normal subjects averaged 50 + 9% (mean + SD), 15 + 3%, and 5 + 4%. The binding of lidocaine and MEGX to serum proteins drawn from seven patients 2 days after their myocardial infarctions averaged 55 + 6% and 14 + 3.0%. Thus percent unbound in patients' serum water was 45% for lidocaine and 86% for MEGX. Since GX binding was only 5% and its total level was so low, it was considered inconsequential and was not studied further.
Heparinized blood stored in red-stoppered Vacutainers had no effect on GX and MEGX plasma concentration levels, but exposure of lidocaine to the stopper lowered the lidocaine concentration level in plasma by 20%.
The octanollbuffer (pH = 7.4) partition coefficient (K,) was 65.0 for lidocaine, 5.7 for MEGX, and 1.3 for GX.
Discussion
The individual ratios of serum levels of MEGX to lidocaine and of GX to lidocaine in the 33 cardiac patients averaged 0.36 + 0.26 and 0.11 + 0.11. These ratios are of the same order as those in the literature.', 12, l6 The intensity of a drug's action is related to its concentration in plasma water, since this establishes the diffusion gradient for the drug to get to the receptor site. The correction factor for converting the total MEGXIlidocaine ratio in serum to that in serum water equals 86%/45%, or 1.9 (protein-binding data from seven patients with a myocardial infarction 2 days before analysis), and therefore the MEGXIlidocaine ratio in serum water averages 0.68 k 0.49. In fact, MEGX levels in serum water were at least 80% or more than those of lidocaine in 11 of the 33 patients. Assuming that MEGX is 0.5 to 1 times as potent as lidocaine for antiarrythmic and toxic effects (since this was the potency observed in animals), then MEGX contributes to the pharmacologic activity of lidocaine therapy in a substantial proportion of lidocaine-treated patients.
The protein binding of lidocaine is known to be increased in several clinical situations, such as recent myocardial infarctionlS~ (applies to most of our patients), increasing age, chronic renal failure, epilepsy (treated), malignancy (reviewed in Routledge et al."), and t r a~m a .~ The increased lidocaine protein-binding is thought to be due to the rise of a,-acid glycoprotein in plasma, which can increase for 5 to 7 days after these events and can remain elevated for as long as 2 to 3 ~k .~, l 4 This implies that the ratio of MEGX to lidocaine in plasma water may be above 0.68 if the patient receiving the lidocaine has a marked increase in levels of this binding protein after myocardial infarction.
Because of the low plasma levels of GX relative to lidocaine, even after correction for protein-binding differences and the low potency of GX in experimental studies relative to lidocaine, we believe that GX contributes very little to the pharmacologic effects of lidocaine.
There is no effect of age on the steady-state MEGX plasma level normalized for lidocaine infusion rate (Fig. 2 ). This conclusion is also reached if one plots the data of Halkin et al. , I 2 but the steady-state GX plasma level normalized for lidocaine dose decreases with age (Fig. 3) . This was unexpected, since GX is eliminated 50% unchanged in the urine,24 and renal function, as measured by endogenous creatinine clearance, decreases in elderly persons.8 This decrease in normalized GX plasma levels in elderly persons may be explained by proposing that GX formation from MEGX is decreased in elderly persons to a greater extent than aging slows the elimination of GX into urine.
Davison et al.7 reported that in only 88 of 362 blood samples drawn from patients with suspected lidocaine toxicity was the lidocaine level above 5 pglml. The remainder of patients apparently had lidocaine levels below this value. Some of the toxic patients had elevated MEGX levels. Lidocaine levels in nontoxic patients were not measured. Buckman et al.3 report that 20 of 44 patients who had lidocaine levels below 6 pglml had toxicity, and all six patients with higher lidocaine levels had toxicity. Lidocaine plasma levels associated with serious toxicity have also been reported to be above 8 pglml." Of our 27 subjects without toxicity, six had serum lidocaine concentrations above 8 pglml. We also observed that five of six subjects with toxicity had lidocaine levels below 8 pglml. In fact, the only difference we observed between the toxic aid nontoxic patients in our study (Table 11) was that, on the average, the toxic patients had higher MEGX levels. The implication is that MEGX contributes to toxicity during lidocaine therapy. We therefore suggest that the concept of a single value for the upper limit of the therapeutic range for serum lidocaine concentration is an oversimplification because it does not take into account individual difference in protein binding of the parent drug or active metabolite accumulation.
Three elderly subjects (ages above 65 yr) had very rapid lidocaine clearance values and clearly represented a different patient population from the remainder of the elderly subjects. Review of the charts of these patients gave no reason for their high clearance values. In a much smaller study, Nation et al." observed one elderly subject who had a lidocaine clearance value that was more than 2 SD above the mean of the values of the other elderly subjects.
The ratio of lidocaine, MEGX, and GX renal clearance to creatinine clearance is below 1.0 for most of our patients, indicating that net renal tubular secretion of these compounds does not occur. However, the high lipid solubility of lidocaine and MEGX (K, substantially above 1.0), and to a lesser extent of GX (K, = 1.3), permits diffusion of these compounds from the urine in the renal tubules back into the blood. This may mask any renal tubular secretion of these basic compounds into the urine.
Lidocaine is more lipophilic (highest K,) than its two metabolites, MEGX and GX, and is 50% bound to plasma proteins in normal subjects. GX is the least lipophilic (lowest K,) of these three compounds and is only 5% bound to plasma proteins. MEGX is of intermediate polarity and protein binding.
Several years ago Stargel et reported that collecting blood in red-stoppered Vacutainer tubes caused about a 28% reduction in lidocaine serum levels. We confirmed this; it still is a problem. It has been proposed that the chemical tris(2-butoxyethyl)phosphate, which is present in the rubber stopper, is leached out and displaces this basic drug from its serum protein binding sites. The drug then redistributes into the erythrocytes, producing spuriously low serum levels. Collecting blood in red-stoppered lated metabolite. CLIN PHARMACOL THER 17:
Vacutainers had no effect on serum levels of [669] [670] [671] [672] [673] [674] [675] [676] 1975 
